The current standard therapy for the treatment of wet-AMD is repeated intravitreal injections of antibodies against vascular endothelial growth factor (VEGF) (Aiello et al., 1995; Ferrara et al., 2006). The gene discussed is VEGFA; the disease is wet macular degeneration.